ABSTRACT
Objective:To investigate the therapeutic effects of conbercept combined with retinal laser photocoagulation on diabetic macular edema (DME) and the effects of the combined therapy on best corrected visual acuity, macular fovea thickness, vascular endothelial growth factor (VEGF) and human stromal cell-derived factor 1 (SDF-1) levels in aqueous humor of patients with DME.Methods:Ninety patients with DME who received treatment in Lishui People's Hospital between November 2016 and December 2019 were included in this study. They were randomly assigned to undergo retinal laser photocoagulation (control group, n = 45) or retinal laser photocoagulation combined with conbercept treatment (study group, n = 45). Therapeutic effects, best corrected visual acuity, macular fovea thickness, and VEGF and SDF-1 levels in aqueous humor were compared between the two groups. The incidence of complications was compared between the two groups. Results:Total response rate in the study group was significantly higher than that in the control group [88.89% (40/45) vs. 68.89% (31/45), χ2 = 5.40, P = 0.020]. After 3 months of treatment, VEGF and SDF-1 levels in aqueous humor were (138.71 ± 16.82) ng/L and (415.18 ± 24.87) mg/L, respectively, which were significantly lower than those in the control group [(276.13 ± 15.96) ng/L, (526.06 ± 22.91) mg/L, t = 39.76, 21.98, both P < 0.001]. After 3 months of treatment, macular fovea thickness and best corrected visual acuity in the study group were (339.52 ± 30.12) μm and 0.47 ± 0.08, respectively, which were significantly lower than those in the control group [(398.65 ± 28.23) μm, 0.36 ± 0.09, t = 6.13, 9.61, both P < 0.01]. There was no significant difference in the incidence of complications between the two groups [13.33% (6/45) vs. 11.11% (5/45), χ2 = 0.10, P > 0.05]. Conclusion:Conbercept combined with retinal laser photocoagulation for the treatment of DME has a definite therapeutic effect. The combined therapy can greatly improve the best corrected visual acuity, reduce macular fovea thickness, decrease VEGF and SDF-1 levels in aqueous humor, and does not increase the incidence of complications. Findings from this study have a certain clinical application value.
ABSTRACT
@#AIM: To investigate the efficacy and safety of intravitreal injection of Conbercept ophthalmic injection(COI)combined with photocoagulation in elderly patients with diabetic macular edema(DME)in order to provide a reference for clinical practice. <p>METHODS: In the DME patients admitted to our hospital in August 2016 to June 2018, according to whether the patients were treated with photocoagulation treatment or not, the patients was divided into observation group(photocoagulation treatment combined with COI)in 55 cases of 55 eyes and control group(photocoagulation treatment without COI)in 50 cases, 50 eyes. The clinical outcomes of the two groups after surgery included the best corrected visual acuity(BCVA), foveal retinal thickness(CMT), intraocular pressure and visual field, 30° visual field average light threshold sensitivity, and visual field mean defect value.<p>RESULTS: There was no significant difference in the general data between the two groups(<i>P</i>>0.05). There were statistically significant differences on BCVA(0.63±0.13 <i>vs</i> 0.76±0.19; <i>t</i>=4.123, <i>P</i><0.001), CMT(305.89±58.76 <i>vs</i> 340.26±60.41μm; <i>t</i>=2.954, <i>P</i>=0.004)between observation group and control group, but there was no significant difference between the two groups in the intraocular pressure(12.11±1.82 <i>vs</i> 12.24±1.59mmHg; <i>t</i>=0.389, <i>P</i>=0.700). The value of visual field and the mean visual field defect of the observation group were significantly lower than those of the control group at 1mo after operation(<i>P</i><0.001). The average light threshold sensitivity of the observation group was significantly higher at 30° 1mo after operation than that of the control group, the difference was statistically significant(<i>P</i><0.001). <p>CONCLUSION: Conbercept ophthalmic injection combined with photocoagulation can improve the efficacy and safety of the treatment for diabetic macular edema in diabetic macular edema patients.
ABSTRACT
AIM:To study the efficacy of conbercept intravitreal injection combined with retinal laser photocoagulation therapy and simple laser photocoagulation therapy on macular edema (ME) secondary to retinal vein occlusion (RVO).METHODS:Forty-eight patients (53 eyes) with macular edema secondary to retinal vein occlusion diagnosed by clinical examination from October 2014 to March 2015 were retrospectively analyzed.Among them,28 patients (31 eyes) were treated with conbercept intravitreal injection combined with retinal laser photocoagulation,which was defined as Group A.And simple laser group contained 20 patients (22 eyes),which was defined as Group B.The clinical data including the patients' best-corrected visual acuity (BCVA) and central retinal thickness (CMT) before treatment and 1wk and 3mo after treatment were observed.RESULTS:Followed up for 3mo,the average BCVA values of A and B were 0.44±0.25,0.56±0.24,respectively and the average CMT were 330.50 ± 121.71,354.67 ± 102.79μm at first week of treatment.There was no significant difference in BCVA and CMT of Group A compared with Group B.There was statistically significant in BCVA and CMT of Group A and Group B compared with before treatment (P＜0.05).The average BCVA values of A and B were 0.24±0.18,0.39±0.20,respectively and the average CMT were 252.62 ± 83.01,332.67 ± 102.33μ m at third month of treatment.There were statistically significant differences between the two groups and compared with before treatment (P＜0.05),and Group A was superior to Group B.CONCLUSION:Conbercept intravitreal injection combined with retinal laser photocoagulation therapy and simple laser photocoagulation treatment of macular edema secondary to retinal vein occlusion are both effective that macular edema is significantly reduced,and vision is stable and improved.But for serious cases,conbercept intravitreal injection can reduce retinal edema at first,then combine with retinal laser photocoagulation which has obvious therapeutic effect and it is better than simple laser photocoagulation treatment.
ABSTRACT
Objective To analyze the adverse drug reaction of intravitreal conbercept injection for the security of conbercept injection in clinical application.Methods From 2014 to 2016,248 cases of adverse drug reaction caused by intravitreal conbercept injection were monitored by 62 medical institutions from National Center for Adverse Drug Reaction Monitoring China,and analyzed in this study.Results The adverse drug reactions caused by conbercept were mainly observed in the ophthalmology system,skin system,musculoskeletal system and cardiovascular system.The adverse drug reactions mainly occurred in the early stage of injection.Among those patients,the reported treatment results were cured in 126 cases,improved in 120 cases,unchanged in 1 case,unknown in 1 case,and no anyone died.Conclusion It should give a great attention to the serious adverse reaction that caused by conbercept injection,especially for endophthalmitis,retinal detachment and vitreous hemorrhage.The incidence of serious and newly observed adverse drug reaction should be two important portions of post-marketing safety surveillance.Moreover,the quality of adverse drug reaction reports from different medical institutions needs to be improved.Their assessment and management should be enhanced.
ABSTRACT
Objective To analysis the effect of conbercept ophthalmic injection on peripheral blood vascular endothelial growth factor,intraocular pressure and visual acuity in patients with age related macular degeneration.Methods 60 patients who were diagnosed with age related macular degeneration were collected.All patients were randomly divided into experimental group and control group,30 cases in each group, lucentis intravitreal injection was given into the vitreous cavity in control group, experimental group give conbercept injection into the vitreous cavity,once a month.All patients were treated for 3 months,after the end of treatment,all patients serum VEGF and CRP,CMT,CNV and fluorescence leakage rate,intraocular pressure and visual acuity were detected.ResuIts After treatment,compared with control group,the content of serum VEGF was significantly lower in the experimental group(P<0.05).The content of serum CRP was significantly lower in experimental group(P<0.05).The CMT,CNV and fluorescence leakage rate were significantly lower in the experimental group (P<0.05).The level of IOP and visual acuity(logMAR)were significantly lower in the experimental group (P<0.05).ConcIusions Conbercept ophthalmic injection can reduce age-related macular degeneration patients week blood VEGF and CRP levels and decrease the CMT, CNV and fluorescence leakage rate, reduce intraocular pressure, visual acuity improvement and have guiding significance for clinic.